Moderna, Inc. - Common Stock (NQ:MRNA)

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

October 28, 2024

From Merck & Co., Inc.

Via Business Wire

Moderna Named a Top Employer by Science for Tenth Consecutive Year

October 24, 2024

Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

October 17, 2024

Abbas Hussain Joins Moderna's Board of Directors

October 02, 2024

Moderna R&D Day Highlights Progress and Strategic Priorities

September 12, 2024

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada

September 09, 2024

MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm

October 08, 2024

From The Schall Law Firm

Via Business Wire

MRNA Deadline: Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders With Large Losses to Contact the Firm for Information About Their Rights

October 05, 2024

From Rosen Law Firm

Via Business Wire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

October 04, 2024

IMPORTANT MRNA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA

October 03, 2024

From The Rosen Law Firm PA

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

September 30, 2024

Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines

September 30, 2024

MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline

September 30, 2024

Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403

September 30, 2024

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

September 25, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA

September 24, 2024

From The Rosen Law Firm PA

MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline

September 23, 2024

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

September 21, 2024

if you're looking for a way to escape the market volatility, here are three stocks that are trading near their 52-week lows with solid catalysts for growth

3 Beaten-Down Stocks Ready for a Comeback

September 19, 2024

Via MarketBeat

Topics Economy

Moderna, Inc. REMINDER – MRNA Stockholders Should Contact Robbins LLP for Information About the Moderna, Inc. Class Action and Pending Lead Plaintiff Deadline

September 18, 2024

From Robbins LLP

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

September 17, 2024

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

September 17, 2024

MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline

September 16, 2024

Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax.

Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity

September 16, 2024

Via MarketBeat

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

September 13, 2024

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

September 09, 2024

MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline

September 09, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA

September 09, 2024

From The Rosen Law Firm PA

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

September 05, 2024